Orakl Oncology is a precision oncology company that combines data and biology to bring new drugs to cancer patients.
Orakl Oncology has raised $1.0M in total funding. The most recent round was Non-equity Assistance. The last funding was announced in October 2025.
Orakl Oncology's investors include Bpifrance, Speedinvest, Singular, Amazon Web Services, Verve Ventures.
Orakl Oncology is headquartered in Villejuif, France.
Orakl Oncology is a precision oncology company that combines data and biology to bring new drugs to cancer patients.
Orakl Oncology is at the Non-equity Assistance stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Orakl Oncology — Funding & Investors." VCBacked, October 8, 2025, https://www.vcbacked.co/company/orakl-oncology. Accessed November 12, 2026.
VCBacked. (2025). Orakl Oncology — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/orakl-oncology
{{cite web |title=Orakl Oncology — Funding & Investors |url=https://www.vcbacked.co/company/orakl-oncology |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Orakl Oncology? Request a listing update